The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer
Open accessPublished version of a preprint
Abstract
Abstract Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. Using a phase Ib 3 + 3 dose-escalation and expansion study design, 33 patients with ER and BCL2-positive metastatic disease (mean prior regimens, 2; range, 0–8) were treated with daily tamoxifen (20 mg) and venetoclax (200–800 mg). Apart from uncomplicated “on-target” lymphopenia, no dose-limiting toxicities or high-grade adverse events were observed in the escalation phase (15 patients), and 800 mg was selected as the recommended phase II dose (RP2D). In the expansion phase (18 patients), few high-grade treatment-related adverse events were observed. For 24 patients treated at the RP2D, the confirmed radiologic response rate was 54% and the clinical benefit rate was 75%. Treatment responses were preempted by metabolic responses (FDG-PET) at 4 weeks and correlated with serial changes in circulating tumor DNA. Radiologic responses (40%) and clinical benefit (70%) were observed in 10 patients with plasma-detected ESR1 mutations. Significance: In the first clinical study to evaluate venetoclax in a solid tumor, we demonstrate that combining venetoclax with endocrine therapy has a tolerable safety profile and elicits notable activity in ER and BCL2-positive metastatic breast cancer. These findings support further investigation of combination therapy for patients with BCL2-positive tumors. See related commentary by Drago et al., p. 323. This article is highlighted in the In This Issue feature, p. 305
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, venetoclax limits several features of CLL-associated immunosuppression in patients, including CTL exhaustion and NK-cell dysfunction (de Weerdt et al., 2019) and does not reduce the number of peripheral T cells in patients with HR + BCL2 + metastatic breast cancer (Lok et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Lok et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Upregulation of survival proteins has been implicated in tumor growth and reduced sensitivity to anti-cancer therapy (10,11).”
BackgroundHarris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384 · cited 4×
“The study was supported by funds from a National Health and Medical Research Council (Australia) grant.”
MethodInfluentialMolecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Luminal breast tumors, characterized by estrogen receptor (ER) expression, account for approximately 70% of all breast cancers and are responsible for the majority of breast cancer deaths (1,2).”
BackgroundA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277 · cited 1×
“It is a well-recognized prognostic factor that can be readily assessed by immunohistochemistry or in genomic assays such as Oncotype DX® and PAM50/Prosigna® (15-17).”
MethodSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721 · cited 1×
“It is a well-recognized prognostic factor that can be readily assessed by immunohistochemistry or in genomic assays such as Oncotype DX® and PAM50/Prosigna® (15-17).”
MethodAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 2×
“In pre-clinical studies, endometrial thinning had been observed when tamoxifen was combined with ABT-737, a pre-clinical lead that targets both BCL-2 and BCL-XL (18,27).”
BackgroundABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · cited 2×
“Venetoclax (ABT-199/GDC-0199) is a potent and highly selective inhibitor of BCL-2 (20) (Supplementary Fig.”
BackgroundPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 2×
“Tumor response can be further enhanced with adjunctive therapy that includes mTOR inhibitors (3), isoform-specific PI3K inhibitors (4) and cyclin dependent kinase (CDK) 4/6 inhibitors (5-7).”
BackgroundResultEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“Tumor response can be further enhanced with adjunctive therapy that includes mTOR inhibitors (3), isoform-specific PI3K inhibitors (4) and cyclin dependent kinase (CDK) 4/6 inhibitors (5-7).”
BackgroundAnalysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207 · cited 1×
“These findings are consistent with emerging evidence on the utility of ctDNA in monitoring disease (30).”
ResultSelf-citation
Research works printed but not linked: 1
- Seymour, 2013, Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy show anti-tumor activity including complete remissions in high-risk relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (abstract 7018), Blood, 122, 429s
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Small molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 610
Brett, J. O., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01462-3 · Cited by 414
“Lok SW, et al. A Phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2positive metastatic breast cancer.”
BackgroundMitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
Yamazaki, T., Kirchmair, A., Sato, A., Buqué, A., Rybstein, M., Petroni, G., Bloy, N., Finotello, F., Stafford, L., Navarro Manzano, E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0751-0 · Cited by 359
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Metadata
- Authors
- Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., Liew, D., Liu, H. K., Mann, G. B., Moodie, K., Murugasu, A., Pal, B., Roberts, A. W., Rosenthal, M. A., Shackleton, K., Silva, M. J., Siow, Z. R., Smyth, G. K., Taylor, L., Travers, A., Yeo, B., Yeung, M. M., Bujak, A. Z., Dawson, S.-J., Gray, D. H. D., Visvader, J. E., & Lindeman, G. J.
- Affiliations
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Austin Health (AU)
- Corresponding author
- Lindeman, Geoffrey J.
- ORCID
- Lok, Sheau W.
- Whittle, James R.
- Vaillant, François
- Teh, Charis E.
- Lo, Louisa L.
- Policheni, Antonia N.
- Bergin, Alice R.T.
- Desai, Jayesh
- Ftouni, Sarah
- Gandolfo, Luke C.
- Liew, Danny
- Mann, G. Bruce
- Moodie, Kate
- Pal, Bhupinder
- Roberts, Andrew W.
- Rosenthal, Mark A.
- Silva, Maria João
- Smyth, Gordon K.
- Travers, Avraham
- Yeo, Belinda
- Yeung, Miriam M.
- Bujak, Andjelija Zivanovic
- Dawson, Sarah-Jane
- Gray, Daniel H.D.
- Visvader, Jane E.
- Lindeman, Geoffrey J.
- Venue
- Cancer Discovery
- Published
- 2019-03-01
- Volume
- 9
- Issue
- 3
- Pages
- 354-369
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2902257786
- Cited by
- 148
- References
- 45
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 17 · 2023: 21 · 2022: 21 · 2021: 33 · 2020: 22 · 2019: 11
- FWCI
- 15.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, other-oa)
- Funders
- National Health and Medical Research Council (1016701, 1040978, 1054618, 1078763, 1113133)
- Victorian Cancer Agency (TRP13041, 13-035)
- National Breast Cancer Foundation (NT-13-06)
- NHMRC (1089072, 1090236, 1100807, 1058892, 1037230, 1078730)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- venetoclax, tamoxifen, BCL-2 inhibitor, endocrine therapy, estrogen receptor-positive breast cancer, combination therapy, dose-limiting toxicity, circulating tumor DNA, ESR1 mutations, lymphopenia
- MeSH terms
- Circulating Tumor DNA, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Middle Aged, Neoplasm Metastasis, Sulfonamides, Tamoxifen, Tissue Distribution, Disease-Free Survival, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2, Estrogen Receptor alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-18-1151
- The paper
- Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., Liew, D., Liu, H. K., Mann, G. B., Moodie, K., Murugasu, A., Pal, B., Roberts, A. W., Rosenthal, M. A., Shackleton, K., . . . Lindeman, G. J. (2019). A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-18-1151
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.